<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02654717</url>
  </required_header>
  <id_info>
    <org_study_id>DFD-07-CD-001</org_study_id>
    <nct_id>NCT02654717</nct_id>
  </id_info>
  <brief_title>Eight Week Study of Treatment With DFD-07 for Actinic Keratosis of the Face and Scalp</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Promius Pharma, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Promius Pharma, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how well DFD-07 works in treating actinic keratosis on
      the face and scalp during 8 weeks of treatment. The study will also look at any unwanted
      effects of the study drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Patients With Complete Clearance of Lesions</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent of patients with complete clearance of actinic keratosis (AK) lesions at the end of treatment (8 weeks)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">111</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>DFD-07 cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DFD-07 cream applied twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo cream applied twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DFD-07 Cream</intervention_name>
    <arm_group_label>DFD-07 cream</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <arm_group_label>Placebo cream</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be eligible for the study, the patients have to fulfil all of the following criteria at
        Visit 1:

          1. Written informed consent has been signed and dated prior to any study related
             procedure or initiation of a wash out period

          2. Skin type I, II or III according to Fitzpatrick

          3. 5-8 Actinic Keratosis (AK) mild to moderate grade lesions in an approximately 25 cm2
             region of scalp, forehead or face that are non-hypertrophic and non-hyperkeratotic

          4. 18 years of age or older

          5. Female patients of childbearing potential must agree to use contraception during the
             study which can include abstinence with a secondary contraceptive option should the
             patient become sexually active. All women of childbearing potential must have a
             negative urine pregnancy test (test must have a sensitivity of at least 25 IU/ML for
             human chorionic gonadotropin) at the Baseline Visit. A female is considered of
             childbearing potential unless she is pre-menarche, postmenopausal with no menses for
             at least 12 months or surgically sterile. Reliable methods of contraception are
             hormonal methods or intrauterine devices in use for at least 90 days prior to the
             Baseline Visit or barrier methods plus spermicide use for at least 14 days prior to
             the Baseline Visit or a partner who has had a vasectomy at least 3 months prior to the
             Baseline Visit.

          6. ≥ 60 days washout from prohibited medications:

               -  Masoprocol

               -  5-Fluorouracil

               -  Cyclosporine

               -  Retinoids

               -  Trichloroacetic Acid/Lactic Acid Peel

               -  50% Glycolic Acid Peel

               -  Topical or systemic diclofenac, celecoxib or any other non-sterioda
                  anti-inflammatory drug (however daily low-dose aspirin is allowed, as long as the
                  patient has been on a stable dose, ≤ 100 mg once a day, for 60 days prior to the
                  start of the study.) Note: Patients may use acetaminophen/paracetamol as needed

               -  Photodynamic therapy

               -  Topical or systemic immunomodulating agents including:

                    -  Systemic, topical or intralesional interferon

                    -  Imiquimod (Aldara, Zyclara)

                    -  Topical ingenol mebutate (Picato)

                    -  Topical tacrolimus

                    -  Topical pimecrolimus

                    -  Sirolimus

                    -  Cyclosporin

                    -  Intralesional Bacillus Calmette-Guerin (BCG)

                    -  Topical coal tar products

                    -  Topical or systemic corticosteroids

        Exclusion Criteria:

        Patients who fulfil one or more of the following criteria, will not be eligible for the
        study:

          1. Known or suspected hypersensitivity to any non-steroidal anti-inflammatory drug
             (NSAID) or a component of the formulation of the study medication

          2. Clinical evidence of severe, uncontrolled autoimmune, cardiovascular,
             gastrointestinal, hematological, hepatic, neurologic, pulmonary or renal disease.

          3. Significant history (within the past year) of alcohol or drug abuse

          4. Participation in any clinical research study within 60 days of the Baseline Visit.

          5. Pregnancy, lactation or plans to become pregnant

          6. Concomitant use of cosmetics or other topical drug products on or near the selected
             treatment area. However, the use of topical sunscreens is allowed.

          7. Cosmetic or therapeutic procedures (e.g. laser, peeling, photodynamic therapy) within
             2 weeks and within 2 cm of the selected treatment area.

          8. Other skin conditions within the selected treatment area (e.g. rosacea, psoriasis,
             atopic dermatitis, eczema, basal or squamous cell carcinoma or albinism)

          9. Use of sun lamps or tanning beds or booths during the 14 days prior to the Baseline
             Visit or planned use during the study.

         10. Any systemic cancer therapy within 6 months of the Baseline Visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site One</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Two</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Site Three</name>
      <address>
        <city>Wuppertal</city>
        <zip>42287</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 24, 2015</study_first_submitted>
  <study_first_submitted_qc>January 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2016</study_first_posted>
  <results_first_submitted>October 4, 2018</results_first_submitted>
  <results_first_submitted_qc>October 4, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2019</results_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>DFD-07 Cream</title>
          <description>DFD-07 cream applied twice daily
DFD-07 Cream</description>
        </group>
        <group group_id="P2">
          <title>Placebo Cream</title>
          <description>Placebo cream applied twice daily
Placebo Cream</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-permitted medication</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DFD-07 Cream</title>
          <description>DFD-07 cream applied twice daily
DFD-07 Cream</description>
        </group>
        <group group_id="B2">
          <title>Placebo Cream</title>
          <description>Placebo cream applied twice daily
Placebo Cream</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="56"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="111"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.0" spread="9.27"/>
                    <measurement group_id="B2" value="72.7" spread="6.89"/>
                    <measurement group_id="B3" value="72.4" spread="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Actinic Keratosis lesions</title>
          <units>Number of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="56"/>
                    <count group_id="B2" value="55"/>
                    <count group_id="B3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.1" spread="1.2"/>
                    <measurement group_id="B2" value="6.1" spread="0.99"/>
                    <measurement group_id="B3" value="6.1" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Patients With Complete Clearance of Lesions</title>
        <description>Percent of patients with complete clearance of actinic keratosis (AK) lesions at the end of treatment (8 weeks)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DFD-07</title>
            <description>Patients treated with DFD07 for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Pts treated with vehicle for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Patients With Complete Clearance of Lesions</title>
          <description>Percent of patients with complete clearance of actinic keratosis (AK) lesions at the end of treatment (8 weeks)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Baseline visit until 30 days after the last treatment.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>DFD-07 Cream</title>
          <description>DFD-07 cream applied twice daily
DFD-07 Cream</description>
        </group>
        <group group_id="E2">
          <title>Placebo Cream</title>
          <description>Placebo cream applied twice daily
Placebo Cream</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <description>Aggravation of pre-existing B-cell lymphoma</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiovascular Event</sub_title>
                <description>Patient hospitalized with cardiovascular event (no further specification available).</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Compression fracture of lumbar vertebral body</sub_title>
                <description>Patient immobilized with severe lower back pain.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Knee replacement</sub_title>
                <description>Knee replacement for arthritis</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <description>Nasopharyngitis</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="56"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Srinivas Sidgiddi</name_or_title>
      <organization>Dr. Reddy's Laboratories Inc.</organization>
      <phone>6093759900</phone>
      <email>srinivassidgiddi@drreddys.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

